PortViewPortView
89bio logo

89bio (ETNB) Stock Analysis

NASDAQHealthcareBiotechnology

$14.84+0.00%
1-year price historyRange $4.83 – $14.96
52-week range$14.84
$4.16$15.06

What 89bio does

Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic steatohepatitis (NASH). Furthermore, the company has plans to explore pegozafermin's utility in treating severe hypertriglyceridemia. Founded in 2018, 89bio, Inc. maintains its corporate headquarters in San Francisco, California.

Key metrics

Market cap
$2.20B
P/E (TTM)
-4.02
EPS (TTM)
$-3.69
Beta
1.26
Dividend yield
0.00%
Revenue / share
$0.00
50-day avg
$12.41
200-day avg
$9.75
52-week high
$15.06
52-week low
$4.16
CEO
Rohan Palekar

ETFs linked to ETNB

Broad-market and Healthcare sector ETFs an investor holding 89bio is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ETNB fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze ETNB in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for 89bio?
89bio trades under the ticker ETNB on NASDAQ.
Which exchange is ETNB listed on?
ETNB is listed on NASDAQ.
What sector does 89bio operate in?
89bio is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze ETNB in a portfolio?
PortView shows ETNB's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.